All In Biotech

Drug Trial Radar · NCT04351763

Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms

Last checked: Nov 20, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 804 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

804

Actual

Start

May 20, 2020

Primary completion

May 25, 2021

Study completion Jun 5, 2021

Sponsor

Lead sponsor
Nicolaus Copernicus UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.

Conditions

  • COVID-19

Interventions

  • AmiodaroneDrug

    Ion channel blocker

  • VerapamilDrug

    Ion channel blocker

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical improvementTime frame: Randomization to day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nicolaus Copernicus University

    Bydgoszcz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.